Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 9/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.40 |
| ▸ | ADH5 | P11766 | 1/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2812061 | 0.80 | HDAC6 (0.43) | MMP2MMP3HDAC1HDAC6AKR1C3 | |
| SCHEMBL27702486 | 0.78 | AKR1C3 (0.50) | S1PR1S1PR3FFAR2ADH5AKR1C3 | |
| SCHEMBL402398 | 0.78 | ADH5 (0.58) | S1PR1FFAR2ADH5AKR1C3AKR1C2 | |
| SCHEMBL25383658 | 0.77 | MAPT (0.49) | HDAC1HDAC8HDAC6 | |
| SCHEMBL1739428 | 0.76 | P4HB (0.42) | HDAC1HDAC8HDAC6 | |
| SCHEMBL29788387 | 0.76 | HDAC8 (0.46) | HDAC1HDAC8HDAC6 | |
| SCHEMBL1964418 | 0.76 | HDAC8 (0.46) | HDAC1HDAC8HDAC6 | |
| SCHEMBL17133900 | 0.75 | AKR1C3 (0.60) | S1PR1S1PR3FFAR2ADH5AKR1C3 | |
| SCHEMBL403135 | 0.75 | AKR1C3 (0.55) | S1PR1FFAR2ADH5AKR1C3AKR1C2 | |
| SCHEMBL3903631 | 0.75 | EGFR (0.57) | S1PR1AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644367-B1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | NOVARTIS AG (CH) | 2015-10-14 | — | — | EP | disclosed |
| CN-102174042-B | Immunosuppressant compounds and compositions | IRM LLC | 2013-09-18 | — | — | CN | disclosed |
| CN-102174042-A | Immunosuppressant compounds and compositions | IRM LLC | 2011-09-07 | — | — | CN | disclosed |
| CN-1816544-B | Immunosuppressant compounds and compositions | IRM LLC | 2011-06-08 | — | — | CN | disclosed |
| EP-2233473-A1 | 3,5-di(aryl or heteroaryl)isoxazoles and 1,2,4-oxadiazoles as S1P1 receptor agonists, immunosuppresssive and anti-inflammatory agents | Novartis AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| EP-2233473-A1 | 3,5-di(aryl or heteroaryl)isoxazoles and 1,2,4-oxadiazoles as S1P1 receptor agonists, immunosuppresssive and anti-inflammatory agents | Novartis AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| US-7799812-B2 | Reverse isoxazoles | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| US-7799812-B2 | Reverse isoxazoles | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| US-7799812-B2 | Reverse isoxazoles | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| EP-1981858-B1 | 3,5-DI(ARYL OR HETEROARYL)ISOXAZOLES AND 1,2,4-OXADIAZOLES AS S1P1 RECEPTOR AGONISTS, IMMUNOSUPPRESSSIVE AND ANTI-INFLAMMATORY AGENTS | NOVARTIS AG (CH) | 2010-06-16 | — | — | EP | disclosed |
| CN-101374821-A | 3,5-di(aryl or heteroaryl)isoxazoles and 1,2,4-oxadiazoles as S1P1 receptor agonists, immunosuppresssive and anti-inflammatory agents | NOVARTIS AG (CH) | 2009-02-25 | — | — | CN | disclosed |
| EP-1644367-A4 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2008-12-31 | — | — | EP | disclosed |
| US-7462629-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2008-12-09 | — | — | US | disclosed |
| EP-1981858-A2 | 3,5-DI(ARYL OR HETEROARYL)ISOXAZOLES AND 1,2,4-OXADIAZOLES AS S1P1 RECEPTOR AGONISTS, IMMUNOSUPPRESSSIVE AND ANTI-INFLAMMATORY AGENTS | Novartis AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007085451-A2 | 3,5-DI (ARYL OR HETEROARYL) ISOXAZOLES AND 1, 2, 4-OXADIAZOLES AS S1P1 RECEPTOR AGONISTS, IMMUNOSUPPRESSSIVE AND ANTI -INFLAMMATORY AGENTS | NOVARTIS AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007085451-A2 | 3,5-DI (ARYL OR HETEROARYL) ISOXAZOLES AND 1, 2, 4-OXADIAZOLES AS S1P1 RECEPTOR AGONISTS, IMMUNOSUPPRESSSIVE AND ANTI -INFLAMMATORY AGENTS | NOVARTIS AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| CN-1816544-A | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2006-08-09 | — | — | CN | disclosed |
| EP-1644367-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2006-04-12 | — | — | EP | disclosed |
| US-20050009786-A1 | Immunosuppressant compounds and compositions | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2005-01-13 | — | — | US | disclosed |
| WO-2004113330-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009786-A1 | Immunosuppressant compounds and compositions | ICOS, EDNRA, NFATC1 | S1PR1 133/4885S1PR3 142/4885MMP2 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.